WeVote
Log In

Bill

Bill

S 36

Protect Our Seniors Act

119th Congress Introduced by Rick Scott

Bill S 36 mandates clear labeling for mifepristone and misoprostol, ensuring consumers receive vital information for safer, informed use of these medications.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 36

Summary of Bill S 36

Bill Information

  • Bill Number: S 36
  • Title: Relates to the labeling of mifepristone, misoprostol, and their generic alternatives
  • Status: Signed into law (Chap. 7)
  • Introduced: January 08, 2025
  • Classification: Legislative Bill

Purpose and Intent

Bill S 36 aims to establish specific labeling requirements for mifepristone, misoprostol, and their generic alternatives. The intent of this legislation is to enhance transparency and provide clear information to consumers regarding these medications, which are commonly used in medical abortions and for other health-related purposes.

Key Provisions

  • Labeling Requirements: The bill mandates that all packaging for mifepristone and misoprostol, including their generic versions, must include standardized information. This may encompass dosage instructions, potential side effects, and contraindications.
  • Consumer Information: The legislation emphasizes the importance of providing comprehensive information to consumers to ensure informed decision-making regarding the use of these medications.
  • Compliance Timeline: The bill outlines a timeline for manufacturers to comply with the new labeling standards, although specific dates for implementation are not detailed in the provided information.

Affected Parties

  • Manufacturers: Pharmaceutical companies producing mifepristone, misoprostol, and their generic alternatives will be required to update their labeling practices in accordance with the new law.
  • Healthcare Providers: Medical professionals prescribing these medications will need to be aware of the updated labeling to provide accurate information to patients.
  • Consumers: Individuals seeking these medications will benefit from clearer labeling, which may improve understanding and safety in their use.

Legislative Process and Timeline

  • January 08, 2025: Bill introduced and referred to the Higher Education Committee.
  • January 13, 2025: Amended and recommitted to the Higher Education Committee.
  • January 21, 2025: Passed in the Senate and delivered to the Assembly.
  • January 22, 2025: Passed in the Assembly and substituted for A2145A.
  • February 03, 2025: Delivered to the Governor and signed into law as Chapter 7.

Related Legislation

  • S 9945: A related bill from a prior session that may have addressed similar issues.
  • A 2145: A companion bill that aligns with the objectives of S 36.

Conclusion

Bill S 36 represents a significant step towards improving the labeling of mifepristone and misoprostol, ensuring that consumers have access to essential information about these medications. By establishing clear labeling requirements, the bill aims to promote informed use and enhance patient safety.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.